Aptuit, Inc. has agreed to acquire Evotec AG’s Chemical and Pharmaceutical Development (CPD) business, which includes an API facility in Oxford, England and a recently-expanded parenteral fill/finish facility in Glasgow, Scotland. The acquisition provides Aptuit with an established European presence in API development services. The CPD business provides small molecule API development labs, kilo labs and pilot plants as well as clinical scale parenteral fill/finish including two lyophilization suites.

“This acquisition continues Aptuit’s momentum as we assemble a complete suite of drug development services in all three major geographies in Europe, North America and Asia,” said Michael A. Griffith, chief executive officer and founder of Aptuit. “We will integrate the highly-regarded scientific staff and two pilot plants in Oxford and state-of-the-art parenteral fill/finish capabilities in Glasgow into our existing global network. We will then leverage those capabilities to drive our commercial-scale capabilities in India, providing our clients with world-class drug development services from discovery to commercialization.”

The two companies have also entered into a long-term supply agreement under which Aptuit will provide API and its full range of development services in support of Evotec’s pharmaceutical pipeline. “The deal we announced today will position our Chemical and Pharmaceutical Development business within an environment where it can thrive, and with a global company focused on streamlining and supporting the drug development process for biotechnology and pharmaceutical innovators,” said Jorn Aldag, president and chief executive officer of Evotec.

Aptuit plans to retain all of the employees of the CPD business and, Paul McGee, Evotec’s senior vice president of chemical development in Oxford and Dr. Sandy Allan Evotec’s senior vice president of formulation sciences in Glasgow, will continue in their roles within Aptuit.

The acquisition is expected to close within 75 days and is not subject to financing or other contingencies.